Skip to main content

Advertisement

SpringerLink
Log in

Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Anthracycline is a mainstay in treatment of many cancers including lymphoma and breast cancer among many others. However, anthracycline treatment can be cardiotoxic. Although anthracycline-induced cardiotoxicity is dose dependent, it can also occur early at the onset of treatment and even up to several years following completion of treatment. This review article focuses on the understanding of mechanisms of anthracycline-induced cardiotoxicity, the treatments, and recommended follow-up and preventive approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271–289

    Article  PubMed  Google Scholar 

  2. Henriksen PA (2018) Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 104(12):971–977

    Article  CAS  PubMed  Google Scholar 

  3. Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, Fung K, Anderson GM (2017) A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol 2(1):88–93

    Article  PubMed  Google Scholar 

  4. Bernstein D (2018) Anthracycline cardiotoxicity: worrisome enough to have you quaking? Circ Res 122(2):188–190

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 131(22):1981–1988

    Article  CAS  PubMed  Google Scholar 

  6. Abdelnaby M, Almaghraby A, Saleh Y, Abayazeed R (2018) Pericardial sarcoma. BMJ Case Rep 2018:bcr-2018–bc226112

    Google Scholar 

  7. Jasra S, Anampa J (2018) Anthracycline use for early stage breast cancer in the modern era: a review. Curr Treat Options in Oncol 19(6):30

    Article  Google Scholar 

  8. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 226(4673):466–468

    Article  CAS  PubMed  Google Scholar 

  9. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279(9):8290–8299

    Article  CAS  PubMed  Google Scholar 

  10. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ETH (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639–1642

    Article  PubMed  CAS  Google Scholar 

  11. Beretta GL, Zunino F (2008) Molecular mechanisms of anthracycline activity. Top Curr Chem 283:1–19

    CAS  PubMed  Google Scholar 

  12. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53(2):105–113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Vejpongsa P, Yeh ET (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64(9):938–945

    Article  CAS  PubMed  Google Scholar 

  14. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC (1978) Early anthracycline cardiotoxicity. Am J Med 65(5):823–832

    Article  CAS  PubMed  Google Scholar 

  15. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63–75

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869–2879

    Article  CAS  PubMed  Google Scholar 

  17. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324(12):808–815

    Article  CAS  PubMed  Google Scholar 

  18. Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G (2008) The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 107(3):443–450

    Article  CAS  PubMed  Google Scholar 

  19. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801

    Article  PubMed  Google Scholar 

  20. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA (1967) Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 20(3):333–353

    Article  CAS  PubMed  Google Scholar 

  21. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25(4 Suppl 10):72–85

    CAS  PubMed  Google Scholar 

  22. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE (1998) Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 27(1):53–68

    Article  CAS  PubMed  Google Scholar 

  23. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 266(12):1672–1677

    Article  CAS  PubMed  Google Scholar 

  24. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710–717

    Article  Google Scholar 

  25. Lipshultz SE, Scully RE, Stevenson KE, Franco VI, Neuberg DS, Colan SD, et al. Hearts too small for body size after doxorubicin for childhood ALL: Grinch syndrome. J Clin Oncol. 2014;32(15_suppl):10021-

  26. Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M, Jones LW (2012) Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 126(23):2749–2763

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1–39.e14

    Article  PubMed  Google Scholar 

  28. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15(10):1063–1093

    Article  PubMed  PubMed Central  Google Scholar 

  29. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group, American Society of Echocardiography’s Guidelines and Standards Committee, European Association of Echocardiography (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18(12):1440–1463

    Article  PubMed  Google Scholar 

  30. Bountioukos M, Doorduijn JK, Roelandt JR, Vourvouri EC, Bax JJ, Schinkel AF, Kertai MD, Sonneveld P, Poldermans D (2003) Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. Eur J Echocardiogr 4(4):300–305

    Article  CAS  PubMed  Google Scholar 

  31. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277–314

    Article  PubMed  Google Scholar 

  32. Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L et al (2019) Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging 3178

  33. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596–603

    Article  PubMed  PubMed Central  Google Scholar 

  34. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH (2013) Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr 26(2):185–191

    Article  PubMed  Google Scholar 

  35. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH et al (1981) Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94(4 pt 1):430–435

    Article  CAS  PubMed  Google Scholar 

  36. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ (2000) Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? Eur Heart J 21(16):1387–1396

    Article  CAS  PubMed  Google Scholar 

  37. Naik MM, Diamond GA, Pai T, Soffer A, Siegel RJ (1995) Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography. J Am Coll Cardiol 25(4):937–942

    Article  CAS  PubMed  Google Scholar 

  38. Mogelvang J, Stokholm KH, Saunamaki K, Reimer A, Stubgaard M, Thomsen C et al (1992) Assessment of left ventricular volumes by magnetic resonance in comparison with radionuclide angiography, contrast angiography and echocardiography. Eur Heart J 13(12):1677–1683

    Article  CAS  PubMed  Google Scholar 

  39. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, Bijsterveld P, Ridgway JP, Radjenovic A, Dickinson CJ, Ball SG, Plein S (2012) Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 379(9814):453–460

    Article  PubMed  PubMed Central  Google Scholar 

  40. Fernandez-Jimenez R, Sanchez-Gonzalez J, Aguero J, Del Trigo M, Galan-Arriola C, Fuster V et al (2015) Fast T2 gradient-spin-echo (T2-GraSE) mapping for myocardial edema quantification: first in vivo validation in a porcine model of ischemia/reperfusion. J Cardiovasc Magn Reson 17:92

    Article  PubMed  PubMed Central  Google Scholar 

  41. Fernández-Jiménez R, Barreiro-Pérez M, Martin-García A, Sánchez-González J, Agüero J, Galán-Arriola C, García-Prieto J, Díaz-Pelaez E, Vara P, Martinez I, Zamarro I, Garde B, Sanz J, Fuster V, Sánchez PL, Ibanez B (2017) Dynamic edematous response of the human heart to myocardial infarction. Circulation. 136(14):1288–1300

    Article  PubMed  PubMed Central  Google Scholar 

  42. Nakamori S, Dohi K, Ishida M, Goto Y, Imanaka-Yoshida K, Omori T et al (2018) Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc Imaging 11(1):48–59

    Article  PubMed  Google Scholar 

  43. Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, López GJ, de Molina-Iracheta A, Pérez-Martínez C, Agüero J, Fernández-Jiménez R, Martín-García A, Oliver E, Villena-Gutierrez R, Pizarro G, Sánchez PL, Fuster V, Sánchez-González J, Ibanez B (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73(7):779–791

    Article  PubMed  Google Scholar 

  44. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD (2012) Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 30(23):2876–2884

    Article  PubMed  PubMed Central  Google Scholar 

  45. Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13(5):699–709

    Article  CAS  PubMed  Google Scholar 

  46. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 109(22):2749–2754

    Article  CAS  PubMed  Google Scholar 

  47. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H (2003) Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82(4):218–222

    Article  CAS  PubMed  Google Scholar 

  48. Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D et al (2005) Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 145(4):212–220

    Article  CAS  PubMed  Google Scholar 

  49. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik I, Kes S, Tekuzman G (2005) cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 16(5):798–804

    Article  CAS  PubMed  Google Scholar 

  50. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi GF, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM, Cipolla CM, Cardinale D, Ciceri F, Latini R, Sandri MT, Maggioni AP, Labianca R, Tettamanti M, Senni M, Finzi A, Grosso F, Vago T, Civelli M, Gramenzi S, Masson S, Balconi G, Bernasconi R, Salvatici M, Nicolis E, Barlera S, Magnoli M, Buratti MG, Ojeda Fernandez ML, Franzosi MG, Staszewsky L, Vasamì A, Malossi A, Sicuro M, Thiebat B, Barè C, Corzani A, Coccolo F, Colecchia S, Pellegrini C, Bregni M, Appio L, Caico I, G.Rossetti, Mesenzani O, Campana C, Giordano M, Gilardoni M, Scognamiglio G, Corrado G, Battagin D, de Rosa F, Carpino C, Palazzo S, Monopoli A, Milandri C, Giannessi PG, Zipoli G, Ghisoni F, Rizzo A, Pastori P, Callegari S, Sesenna C, Colombo A, G.Curigliano, Fodor C, Mangiavacchi M, Cavina R, Guiducci D, Mazza R, Turazza FM, Vallerio P, Marbello L, Sala E, Fragasso G, Trinca S, Aquilina M, Rocca A, Farolfi A, Andreis D, Gori S, Barbieri E, Lanzoni L, Marchetti F, Falci C, Bianchi A, Mioranza E, Banzato A, Re F, Gaibazzi N, Gullo M, Turina MC, Gervasi E, Giaroli F, Nassiacos D, Verusio C, Barco B, Bertolini A, Cucchi G, Menatti E, Sinagra G, Aleksova A, Guglielmi A, Pinotti G, Gueli R, Mongiardi C, Vallini I (2018) Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer 94:126–137

    Article  CAS  PubMed  Google Scholar 

  51. Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, di Mauro M, Ficorella C, Penco M (2011) Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 105(11):1663–1668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, Hesse B, Kjaer A (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7(1):87–93

    Article  CAS  PubMed  Google Scholar 

  53. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM (2005) N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51(8):1405–1410

    Article  CAS  PubMed  Google Scholar 

  54. Skovgaard D, Hasbak P, Kjaer A (2014) BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. PLoS One 9(5):e96736

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35(8):893–911

    Article  PubMed  Google Scholar 

  56. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, Nathan PC, Tissing WJ, Shankar S, Sieswerda E, Skinner R, Steinberger J, van Dalen E, van der Pal H, Wallace WH, Levitt G, Kremer LC, International Late Effects of Childhood Cancer Guideline Harmonization Group (2015) Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. The Lancet Oncology 16(3):e123–ee36

    Article  PubMed  PubMed Central  Google Scholar 

  57. Pacciarini MA, Barbieri B, Colombo T, Broggini M, Garattini S, Donelli MG (1978) Distribution and antitumor activity of Adriamycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat Rep 62(5):791–800

    CAS  PubMed  Google Scholar 

  58. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M et al (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96(2):133–139

    Article  CAS  PubMed  Google Scholar 

  59. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD et al (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 20(6):1677–1682

    Article  CAS  PubMed  Google Scholar 

  60. van Dalen EC, van der Pal HJ, Kremer LC (2016) Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 3:Cd005008

    PubMed  Google Scholar 

  61. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185–229

    Article  CAS  PubMed  Google Scholar 

  62. Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Investig 19(4):424–436

    Article  CAS  Google Scholar 

  63. van Dalen EC, Michiels EM, Caron HN, Kremer LC (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. (3):Cd005006

  64. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF (2007) Topoisomerase IIβ-mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67(18):8839–8846

    Article  CAS  PubMed  Google Scholar 

  65. Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV et al (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124(2):617–630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15(4):1333–1340

    Article  CAS  PubMed  Google Scholar 

  67. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15(4):1318–1332

    Article  CAS  PubMed  Google Scholar 

  68. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. The Lancet Oncology 11(10):950–961

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, Slater W, Blum R, Muggia F (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319(12):745–752

    Article  CAS  PubMed  Google Scholar 

  70. Tebbi CK, London WB, Friedman D, Villaluna D, Alarcon PAD, Constine LS et al (2007) Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol 25(5):493–500

    Article  CAS  PubMed  Google Scholar 

  71. van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. (6):Cd003917

  72. Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, Costa RB, Landoni G, Nogueira-Rodrigues A, Ribeiro ALP (2019) Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncology 1(1):68–79

    Article  PubMed  PubMed Central  Google Scholar 

  73. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344(26):1959–1965

    Article  CAS  PubMed  Google Scholar 

  74. Jones SP, Teshima Y, Akao M, Marban E (2003) Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 93(8):697–699

    Article  CAS  PubMed  Google Scholar 

  75. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, Kroemer HK, Schultheiss HP, Tschope C (2009) Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res 69(2):695–699

    Article  CAS  PubMed  Google Scholar 

  76. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, Meriç M, Ağaç MT (2011) Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 58(9):988–989

    Article  PubMed  Google Scholar 

  77. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH (2012) Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 60(23):2384–2390

    Article  CAS  PubMed  Google Scholar 

  78. Abela GS, Leja M, Janoudi A, Perry D, Richard J, De Feijter-Rupp H et al (2019) Relationship between atherosclerosis and certain solid cancer tumors. J Am Coll Cardiol 73(9 Supplement 1):156

    Article  Google Scholar 

  79. Abela GS, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U (2011) Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol 107(12):1710–1717

    Article  CAS  PubMed  Google Scholar 

  80. Cardinale D, Biasillo G, Cipolla CM (2016) Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep 18(6):51

    Article  PubMed  Google Scholar 

  81. Taskin E, Kindap EK, Ozdogan K, Aycan MBY, Dursun N (2016) Acute Adriamycin-induced cardiotoxicity is exacerbated by angiotension II. Cytotechnology. 68(1):33–43

    Article  CAS  PubMed  Google Scholar 

  82. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 114(23):2474–2481

    Article  CAS  PubMed  Google Scholar 

  83. Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, Galanopoulos A, Georgiakodis F, Zimeras S, Kyriakidis M, Ahimastos A (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 85(11):894–896

    Article  CAS  PubMed  Google Scholar 

  84. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61(23):2355–2362

    Article  CAS  PubMed  Google Scholar 

  85. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671–1680

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A (2015) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17(1):81–89

    Article  CAS  PubMed  Google Scholar 

  87. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, Wallace KB (2004) Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200(2):159–168

    Article  CAS  PubMed  Google Scholar 

  88. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Oguzhan A, Eryol NK, Topsakal R, Ergin A, Inanc T (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48(11):2258–2262

    Article  CAS  PubMed  Google Scholar 

  89. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, Kalay N, Dikilitas M, Yarlioglues M, Karaca H, Berk V, Ardic I, Ergin A, Lam YY (2013) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 167(5):2306–2310

    Article  PubMed  Google Scholar 

  90. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Goncalves Brandao SM, VOC R et al (2018) Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY Trial. J Am Coll Cardiol 71(20):2281–2290

    Article  CAS  PubMed  Google Scholar 

  91. Cascales A, Pastor-Quirante F, Sánchez-Vega B et al (2013) Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist. 18(4):446–453. https://doi.org/10.1634/theoncologist.2012-0239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH (2014 Mar) Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 15(3):324–331

    Article  PubMed  Google Scholar 

  93. Elitok A, Oz F, Cizgici AY et al (2014) Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up. Cardiol J 21(5):509–515

    Article  PubMed  Google Scholar 

  94. Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G et al (2016) Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology. 134(1):47–53

    Article  CAS  PubMed  Google Scholar 

  95. Nabati M, Janbabai G, Baghyari S et al (2017) Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol 69(5):279–285

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Michigan State University, East Lansing, MI, USA

    Yehia Saleh & Khader Herzallah

  2. Department of Internal Medicine, Cardiology, Michigan State University, 788 service road, Room B-208, Clinical Center, East Lansing, MI, USA

    Ola Abdelkarim & George S. Abela

Authors
  1. Yehia Saleh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ola Abdelkarim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Khader Herzallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George S. Abela
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George S. Abela.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saleh, Y., Abdelkarim, O., Herzallah, K. et al. Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Fail Rev 26, 1159–1173 (2021). https://doi.org/10.1007/s10741-020-09968-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-020-09968-2

Keywords

Search

Navigation